Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.

BMC Cancer · 2024 · PMC11247748 · PMID 39009968

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, the multicenter, prospective phase 3 clinical trials CheckMate 722 and KEYNOTE-789, which aimed to validate the efficacy of ICI plus chemotherapy in patients with NSCLC who presented with EGFR mutation, showed a trend of prolonged PFS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.